New biopharma listings remained strong in May, with the sector continuing to attract capital as public financings held up through the first five months of 2026. One high-profile datapoint: Hemab surged 89% on debut, underscoring ongoing investor appetite for new entrants, while aggregate biopharma funding for the period reached $49.46 billion.